S100B and NSE serum levels in obstructive sleep apnea syndrome
S100B and NSE serum levels in obstructive sleep apnea syndrome
复制标题
DOI：
10.1016/j.sleep.2005.12.012
复制
发表时间：
2006-08-01
期刊：
影响因子：
4.8
通讯作者：
Souza, Diogo Onofre
中科院分区：
文献类型：
--
作者：
Braga, Carla W.;Martinez, Denis;Souza, Diogo Onofre
背景和目的：阻塞性睡眠呼吸暂停综合征（OSAS）是一种慢性疾病，从无害到危及生命，并导致大脑改变表现为神经精神症状。神经元特异性烯醇化酶（NSE）和星形胶质细胞蛋白S10013是脑损伤的敏感外周生化标志物。在目前的工作中，我们测量了血清中的S 10013和NSE的水平，以评估OSAS的有害影响brain.Patients和方法：我们研究了29例男性OSAS患者和17名男性无症状的对照组与呼吸暂停低通气指数（AHI）小于5个事件每小时。通过整夜多导睡眠图（PSG）和简易国际神经精神访谈（MINI）评估患者和对照组是否存在神经精神症状。结果：OSAS组的AHI为27 ± 25 AH/h，范围为5 ~ 99 AH/h。S100 B在OSAS组（0.15 ± 0.09 μ g/l）高于对照组（0.08 ± 0.06 μ g/l; P < 0.01）。两组的血清NSE相似（17.5 +/- 12.2 vs. 15.8 +/- 6.8 ng/ml）。结论：本研究中我们报道了OSAS患者血清S100 B水平升高。(c)2006 Elsevier B. V.保留所有权利。
Background and purpose: Obstructive sleep apnea syndrome (OSAS) is a chronic disease ranging from innocuous to life-threatening and causes brain alterations manifested by neuropsychiatric symptoms. Neuron-specific enolase (NSE) and the astrocytic protein S 10013 are established sensitive peripheral biochemical markers of brain injury. In the present work we measured the serum levels of S 10013 and NSE in order to evaluate the deleterious effects of OSAS to the brain.Patients and methods: We studied 29 male patients with OSAS and 17 male asymptomatic control subjects with an apnea-hypopnea index (AHI) less than five events per hour. Patients and control subjects were evaluated by full-night polysomnography (PSG) and by Mini International Neuropsychiatric Interview (MINI) for the presence of neuropsychiatric symptoms. In the morning following the PSG, blood was collected and serum levels of S100B and NSE were measured using standard techniques.Results: The AHI in the OSAS group was (mean +/- SD) 27 +/- 25 AH/h, ranging from 5 to 99 AH/h. S100B was higher in OSAS (0.15 +/- 0.09 mu g/l) than in the control group (0.08 +/- 0.06 mu g/l; P < 0.01). Serum NSE was similar in both groups (17.5 +/- 12.2 vs. 15.8 +/- 6.8 ng/ml).Conclusions: We report elevated serum S100B levels in OSAS patients in this study. (c) 2006 Elsevier B.V. All rights reserved.